2-Methylbenzo[d]oxazole-4-carbaldehyde | 446864-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-Methylbenzo[d]oxazole-4-carbaldehyde
• 英文别名: 2-methyl-1,3-benzoxazole-4-carbaldehyde
• CAS: 446864-46-6
• 化学式: C₉H₇NO₂
• 分子量: 161.16
• InChiKey: GGURWNPQQILNHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基-7-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吲哚 在 臭氧 、 三氟乙酸 作用下， 以 乙醇 、 水 为溶剂， 反应 0.66h， 生成 2-Methylbenzo[d]oxazole-4-carbaldehyde
  参考文献：
  名称：

  一锅法氧化水解-氧化裂解7-硼基吲哚使得能够获得邻氨基酚和4-酰基苯并恶唑。

  摘要：

  7-Borylindoles进​​行芳基硼酸酯的一锅氧化水解和吲哚C2-C3双键的氧化裂解，得到邻氨基苯酚衍生物。随后的环化作用将生成在C4处带有酰基的苯并恶唑，这是真菌衍生的苯并恶唑生物碱所共有的取代模式。使用7-硼基吲哚作为底物来获得官能化的邻氨基苯酚，可以避免从芳烃制备这些化合物的困难，简化了该方法中对取代的4-酰基苯并恶唑的获取。

  DOI：

  10.1039/c9cc09807k

文献信息

• Dihydropyrazolopyridine compounds and pharmaceutical use thereof
  申请人：——

  公开号：US20040052822A1

  公开（公告）日：2004-03-18

  The present invention provides dihydropyrazolopyridine compounds represented by the formula (I): 1 wherein each symbol is as defined in the specification, optically active forms thereof, and pharmaceutically acceptable salts thereof and hydrates thereof. The compounds of the present invention show a selective and strong inhibitory activity on glycogen synthase kinase-3 beta (GSK-3&bgr;), and are useful as medicaments for prevention and/or treatment of diabetes, diabetic complications and neurodegenerative diseases or as immunopotentiators.

  本发明提供了由式(I)所表示的二氢吡唑吡啶化合物：其中每个符号如规范中所定义，其光学活性形式和药学上可接受的盐及其水合物。本发明的化合物在糖原合酶激酶-3 beta（GSK-3β）上表现出选择性和强烈的抑制活性，并可用作预防和/或治疗糖尿病、糖尿病并发症和神经退行性疾病或作为免疫增强剂的药物。
• DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1355909A2

  公开（公告）日：2003-10-29
• INHIBITORS OF APOL1 AND METHODS OF USING SAME
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20220106327A1

  公开（公告）日：2022-04-07

  The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
• US6977262B2
  申请人：——

  公开号：US6977262B2

  公开（公告）日：2005-12-20
• [EN] DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] COMPOSES DE DIHYDROPYRAZOLOPYRIDINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2002062795A2

  公开（公告）日：2002-08-15

  The present invention provides dihydropyrazolopyridine compounds represented by the formula (I): wherein each symbol is as defined in the specification,optically active forms thereof, and pharmaceutically acceptable salts thereof and hydrates thereof. The compounds of the present invention show a selective and strong inhibitory activity on glycogen synthase kinase-3 beta (GSK-3β), and are useful as medicaments for prevention and/or treatment of diabetes, diabetic complications and neurodegenerative diseases or as immunopotentiators.